Technical Analysis for EBS - Emergent Biosolutions, Inc.

Grade Last Price % Change Price Change
grade F 43.11 0.98% 0.42
EBS closed up 0.98 percent on Tuesday, July 23, 2019, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Aug 2

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical EBS trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bearish Engulfing Bearish 0.98%
Oversold Stochastic Weakness 0.98%
Oversold Stochastic Weakness -2.36%
Stochastic Buy Signal Bullish -1.87%
Lower Bollinger Band Walk Weakness -1.87%
Oversold Stochastic Weakness -1.87%
Lower Bollinger Band Touch Weakness 1.65%

Older signals for EBS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.
Medicine Medical Specialties Pharmaceutical Drugs Solid Tumors Influenza Rheumatoid Arthritis Inflammatory Bowel Disease Vaccination FDA Chronic Lymphocytic Leukemia Vaccines Biological Warfare Anthrax Chemical Warfare Agents Preclinical Preclinical Product
Is EBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 73.89
52 Week Low 39.64
Average Volume 376,262
200-Day Moving Average 55.9482
50-Day Moving Average 44.5742
20-Day Moving Average 44.872
10-Day Moving Average 43.444
Average True Range 1.4745
ADX 15.95
+DI 18.3426
-DI 25.6704
Chandelier Exit (Long, 3 ATRs ) 44.8265
Chandelier Exit (Short, 3 ATRs ) 46.5135
Upper Bollinger Band 48.3954
Lower Bollinger Band 41.3486
Percent B (%b) 0.25
BandWidth 15.704225
MACD Line -0.7197
MACD Signal Line -0.5611
MACD Histogram -0.1586
Fundamentals Value
Market Cap 1.77 Billion
Num Shares 41.1 Million
EPS 1.57
Price-to-Earnings (P/E) Ratio 27.46
Price-to-Sales 3.22
Price-to-Book 2.65
PEG Ratio 1.56
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.34
Resistance 3 (R3) 44.23 43.70 44.14
Resistance 2 (R2) 43.70 43.39 43.76 44.07
Resistance 1 (R1) 43.41 43.20 43.56 43.52 44.00
Pivot Point 42.88 42.88 42.96 42.94 42.88
Support 1 (S1) 42.59 42.57 42.74 42.70 42.22
Support 2 (S2) 42.06 42.38 42.12 42.15
Support 3 (S3) 41.77 42.06 42.09
Support 4 (S4) 41.88